Shots:

• The SMILE study involves assessing of MiniMed 640G system with SmartGuard technology vs insulin pump therapy without continuous glucose monitoring (CGM) in 153 adults with T1D- prone to severe hypoglycemia for 6mos. across 16 centers
• The SMILE study demonstrated a reduction in both biochemical and severe hypoglycemia (84%) without increasing HbA1c levels- improvement in Time in Range spent by patients using the MiniMed 640G system with SmartGuard Suspend before low
• Medtronic’s SmartGuard technology imitates the function of the healthy pancreas with insulin delivery feature (suspend before low) when the glucose level is approaching to its lower limit- thus preventing hypoglycemic attacks

Ref: GlobeNewsWire | Image: Medtronics